Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bone Biologics Corp. BBLG

Healthcare  —  Biotechnology
0.50 0.01 2.04% as of 25 Sep
Market cap
$1.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bone Biologics Corp. (BBLG) Business Profile

Updated before January 2025

Company Overview

Bone Biologics Corp. (BBLG) is a biotechnology company specializing in regenerative medicine, with a primary focus on developing orthobiologic products for bone regeneration. The company was founded in 2004 and is headquartered in Burlington, Massachusetts, USA. BBLG was established with the mission of advancing bone repair and regeneration technologies to address unmet medical needs in orthopedics. The company operates under the leadership of key executives, including its CEO, Jeffrey Frelick, who brings extensive experience in the medical device and biotechnology sectors. BBLG’s leadership team is composed of seasoned professionals with expertise in research, development, and commercialization of medical technologies.

Core Business Segments

Bone Biologics Corp. focuses on the development of orthobiologic products, with its flagship technology being the NELL-1 protein. The company’s core business segments include:

1. Bone Regeneration Technologies

  • NELL-1 Protein: The company’s proprietary NELL-1 protein is a recombinant human protein that promotes bone growth and regeneration. It is designed to enhance the body’s natural bone-healing processes and is particularly effective in spinal fusion procedures and other orthopedic applications.
  • Spinal Fusion Applications: BBLG is actively developing solutions for spinal fusion surgeries, which are critical for treating conditions such as degenerative disc disease and spinal deformities.

2. Orthopedic Applications

  • Trauma and Fracture Repair: The company is exploring the use of its NELL-1 technology in trauma cases, including complex fractures that require enhanced bone healing.
  • Osteoporosis Treatment: BBLG is investigating the potential of its technology to address bone density issues associated with osteoporosis, aiming to improve patient outcomes.

3. Research and Development Services

  • Preclinical Studies: BBLG conducts extensive preclinical research to validate the safety and efficacy of its products.
  • Collaborative Research: The company partners with academic institutions and industry leaders to advance its technology and explore new applications.

Business Model

Bone Biologics Corp. operates on a business model centered around innovation, research, and strategic partnerships. The company generates revenue through the following channels:

  • Product Development and Licensing: BBLG develops proprietary technologies and licenses them to medical device manufacturers and healthcare providers.
  • Collaborative Agreements: The company collaborates with research institutions and industry partners to co-develop products and share intellectual property rights.
  • Clinical Trials and Commercialization: BBLG invests in clinical trials to bring its products to market, with a focus on achieving regulatory approvals and commercial success.

The company’s approach emphasizes the integration of cutting-edge science with practical medical applications, ensuring that its products meet the highest standards of safety and efficacy.

Strategic Direction

Bone Biologics Corp. is committed to advancing its position as a leader in regenerative medicine. The company’s strategic priorities include:

  • Expanding Product Portfolio: BBLG aims to develop new applications for its NELL-1 technology, including treatments for osteoporosis and other bone-related conditions.
  • Global Market Expansion: The company is exploring opportunities to enter new markets, particularly in regions with high demand for advanced orthopedic solutions.
  • Sustainability Goals: BBLG is dedicated to minimizing its environmental impact by adopting sustainable practices in its research and manufacturing processes.
  • Innovation and Research: The company continues to invest in research and development to stay at the forefront of regenerative medicine and orthobiologics.

Competitive Landscape

Bone Biologics Corp. operates in a competitive market, facing competition from both established players and emerging startups in the orthobiologics and regenerative medicine sectors. Key competitors include:

  • Medtronic: A global leader in medical technology, offering a wide range of orthopedic and spinal products.
  • Stryker Corporation: Known for its innovative orthopedic implants and surgical solutions.
  • Zimmer Biomet: A major player in musculoskeletal healthcare, providing advanced bone repair and regeneration products.
  • NuVasive: Specializes in minimally invasive spinal surgery technologies and orthobiologics.

BBLG differentiates itself through its proprietary NELL-1 technology, which offers unique advantages in bone regeneration compared to traditional methods.

Risk Factors

Bone Biologics Corp. faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The company’s products must undergo rigorous regulatory approval processes, which can be time-consuming and costly.
  • Market Dependence: BBLG relies heavily on the success of its NELL-1 technology, making it vulnerable to market fluctuations and competitive pressures.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply chain, particularly for raw materials and manufacturing components.
  • Financial Constraints: As a development-stage company, BBLG may face challenges in securing sufficient funding to support its research and commercialization efforts.

Recent Developments

Bone Biologics Corp. has made significant progress in recent years, including:

  • Advancements in NELL-1 Technology: The company has achieved key milestones in the development and testing of its NELL-1 protein, demonstrating its potential for improving bone regeneration outcomes.
  • Collaborative Partnerships: BBLG has entered into strategic partnerships with leading research institutions to accelerate the development of its products.
  • Regulatory Approvals: The company is actively pursuing regulatory approvals for its products in major markets, including the United States and Europe.
  • Response to Global Developments: BBLG has adapted its operations to address challenges posed by the COVID-19 pandemic, ensuring continuity in research and development activities.

Investment Considerations

Investors considering Bone Biologics Corp. should weigh the following factors:

Strengths

  • Innovative Technology: BBLG’s proprietary NELL-1 protein offers a unique solution for bone regeneration, with significant market potential.
  • Experienced Leadership: The company’s management team has a proven track record in the biotechnology and medical device industries.
  • Growing Market Demand: The global market for orthobiologics is expanding, driven by an aging population and increasing prevalence of orthopedic conditions.

Risks

  • Early-Stage Company: BBLG is still in the development phase, with limited revenue and a high dependence on external funding.
  • Regulatory Uncertainty: The approval process for medical products can be unpredictable, posing risks to the company’s timeline and financial performance.
  • Competitive Pressure: The orthobiologics market is highly competitive, with established players and new entrants vying for market share.

Conclusion

Bone Biologics Corp. is a promising player in the regenerative medicine and orthobiologics sectors, with a strong focus on innovation and collaboration. The company’s proprietary NELL-1 technology positions it as a leader in bone regeneration, offering significant potential for growth and market expansion. While BBLG faces challenges associated with its early-stage status and competitive landscape, its commitment to research and development, coupled with a growing demand for advanced orthopedic solutions, provides a solid foundation for future success.